The invention relates to an intra-dermally, sub-dermally or topically administrable growth factor concentrate derived from approximately 250 xl06 to 5000 x106 human platelets per ml for treating periorbital hyperpigmentation. The concentrate comprises approximately 900 to 2000 pg/ml of Epidermal growth factor (EGF), 30 to 300 pg/ml of Vascular Endothelial growth factor(VEGF), 20 to 100 pg/ml of Basic fibroblast growth factor (b-FGF), 40000 to 120000 pg/ml of Transforming growth factor-P (TGF- P) and 200000 to 600000 pg/ml of Platelet Derived growth factor-AB (PDGF-AB).
